|Articles|December 15, 2013

Creating Better Medicines through Better Conjugation (PDF)

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.

To view a PDF of this article from the BioPharm International archives, click this link

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Creating Better Medicines through Better Conjugation (PDF)

Newsletter

Trending on BioPharm International

Achieving Real Impact Navigating the Data and Regulatory Barriers to AI Adoption in Bio/pharma

How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?

How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain

BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints

RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback